0.00Open7.10Pre Close0 Volume0 Open Interest260.00Strike Price0.00Turnover1760.03%IV9.28%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry7.10Extrinsic Value100Contract SizeAmericanOptions Type-0.8994Delta0.0172Gamma39.26Leverage Ratio-434.6326Theta0.0000Rho-35.31Eff Leverage0.0010Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet